Inhalation Sciences wins new purchase order worth 276,450 Euro (3.2 MSEK)

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB’s aerosol generating platform PreciseInhale and its unique cell exposure module.

The returning client is a loyal customer and has long been a keen advocate of ISAB’s unique multi-modular, precision dosing aerosol system PreciseInhale. Within inhalation the customer has an extensive, competitive portfolio and robust pipeline.

PreciseInhale – reducing risk and costs

PreciseInhale is unique within inhaled drug development as a ‘precision dosing’ system. Unlike standard ‘tower testing’ systems, it customizes the individual aerosol dose to individual test animals. This achieves exceptionally high-precision and predictive data in the preclinical stages, so reducing risk and costs in later clinical stages.

Leading the way in in vitro testing

The advantages of in vitro testing are becoming increasingly understood in inhalation drug development. In vitro dissolution methods like the ones designed by ISAB can generate predictive IVIVC (in vitro in vivo correlated) data early on that enable poor Drug Candidates to be eliminated, reducing costs and accelerating development.

CEO Manoush Masarrat: “it is a great validation when an existing customer returns once again. This time to purchase another main platform system and a new test module. We are grateful for their continued confidence in our products - and proud that our technology has made a positive contribution to their impressive inhalation portfolio”

For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153